Pasithea Therapeutics KTTA Income Statement (2020-2026)

NASDAQ KTTA
$0.48 -0.01 (-2.29%)
As of: Aug 20, 2026 · 3:59 PM EDT
Income Statement Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
0.41M0.45M0.52M1.15M1.33M1.33M1.30M1.31M1.31M1.04M1.04M1.04M1.04M1.04M1.10M2.21M5.64M7.44M7.03M24.94M
Revenue & cost
Revenue (Quarter)
0.01M0.01M0.22M0.24M
Gross Profit (Quarter)
721.00-0.00M0.13M0.24M
Operating items
Research & Development (Quarter)
1.16M1.39M1.10M2.03M1.62M3.35M1.75M2.36M1.58M7.20M1.73M0.04M1.36M7.94M2.94M
Selling, General & Administrative (Quarter)
0.73M1.27M1.95M2.41M0.43M3.22M3.94M2.12M1.80M2.16M1.80M2.29M1.59M1.42M1.75M1.95M1.66M1.75M7.51M1.93M
Restructuring Costs (Quarter)
0.33M655.0045.00
Operating Expenses (Quarter)
0.73M1.27M1.95M2.73M0.43M4.38M5.32M3.21M3.83M3.79M5.15M4.04M3.95M3.00M8.95M3.68M1.71M3.11M15.45M4.88M
Operating Income (Quarter)
-0.73M-1.27M-1.96M-2.40M-3.51M-4.25M-5.08M-3.21M-3.83M-3.79M-5.15M-4.04M-3.95M-3.00M-3.26M-3.68M-3.81M-3.11M-10.26M-4.88M
EBIT (Quarter)
-0.73M-1.27M-1.96M-2.40M-3.51M-4.25M-5.08M-3.21M-3.83M-3.79M-5.15M-4.04M-3.95M-3.00M-3.26M-3.68M-3.81M-3.11M-10.26M-4.88M
Non-operating items
Non Operating Investment Income (Quarter)
-0.01M
Interest & Investment Income (Quarter)
0.13M0.17M0.15M0.11M0.08M0.08M0.05M0.05M0.04M0.18M0.45M
Other Non Operating Income (Quarter)
0.04M-277.00-0.01M0.12M0.15M0.11M0.01M0.01M-0.03M0.02M-0.01M
Non Operating Income (Quarter)
-0.25M2.59M0.83M0.42M-0.34M-0.05M0.23M0.18M0.12M0.18M0.08M0.00M0.08M0.12M0.09M0.07M0.15M2.01M
Net income details
EBT (Quarter)
-0.73M-1.53M0.63M-1.57M-2.66M-4.59M-5.12M-3.27M-3.60M-3.61M-5.03M-3.86M-3.87M-3.00M-3.18M-3.56M-3.72M-3.04M-10.11M-2.87M
Profit After Tax (Quarter)
-0.73M-1.53M0.62M-1.57M-2.66M-4.67M-5.11M-3.54M-3.76M-3.62M-5.49M-3.86M-3.87M-3.03M-3.18M-3.56M-3.72M-3.04M-10.11M-2.87M
Income from Continuing Operations (Quarter)
-0.73M-1.53M0.63M-1.57M-2.66M-4.59M-5.12M-3.27M-3.60M-3.61M-5.03M-3.86M-3.87M-3.00M-3.18M-3.56M-3.72M-3.04M-10.11M-2.87M
Income from Discontinued Operations (Quarter)
-0.47M-0.40M
Consolidated Net Income (Quarter)
-0.73M-1.53M0.63M-0.33M-0.47M0.40M-3.42M-0.27M-0.17M-0.08M-3.86M-3.87M-3.00M-3.18M-3.56M-3.72M-3.04M-10.11M-2.87M
Income towards Parent Company (Quarter)
-0.73M-1.53M0.63M-0.33M-0.47M0.40M-3.42M-0.27M-0.17M-0.08M-3.86M-3.87M-3.00M-3.18M-3.56M-3.72M-3.04M-10.11M-2.87M
Net Income towards Common Stockholders (Quarter)
-0.73M-1.53M0.63M-0.33M-0.47M0.40M-3.42M-0.27M-0.17M-0.08M-3.86M-3.87M-3.00M-3.18M-3.56M-3.72M-3.04M-10.11M-2.87M
Additional items
EPS (Basic) (Quarter)
-1.76-3.411.21-0.28-0.400.30-2.71-0.21-0.13-0.07-3.70-3.71-2.87-2.90-1.61-0.66-0.41-1.44-0.12
EPS (Diluted) (Quarter)
-1.76-3.411.21-0.28-0.400.30-2.71-0.21-0.13-0.07-3.70-3.71-2.87-2.90-1.61-0.66-0.41-1.44-0.12
Shares Outstanding (Quarter)
0.41M0.45M0.52M1.15M1.17M1.33M1.26M1.30M1.31M1.26M1.23M1.04M1.04M1.04M1.10M2.21M5.64M7.44M7.03M24.34M
Shares Outstanding (Diluted) (Quarter)
0.41M0.45M0.52M1.15M1.17M1.33M1.26M1.30M1.31M1.26M1.23M1.04M1.04M1.04M1.10M2.21M5.64M7.44M7.03M24.34M
EBITDA (Quarter)
-0.73M-1.27M-1.96M-2.40M-3.51M-4.25M-5.08M-3.21M-3.83M-3.79M-5.15M-4.04M-3.95M-3.00M-3.26M-3.68M-3.81M-3.11M-10.26M-4.88M
Interest Expenses (Quarter)
0.93M0.02M0.63M0.63M0.63M0.63M0.63M1.89M1.26M0.63M0.63M0.08M0.63M